Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT

Relapse Prophylaxis With IL-15 Super Agonist N-803 in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome Following Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation

This is a single-arm, multi-center Phase II trial using IL-15 super-agonist complex (N-803 formerly known as Alt-803) maintenance after allogeneic hematopoietic cell transplant (alloHCT) for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).

Study Overview

• Status: Completed
• Conditions: Myelodysplastic Syndrome (MDS); Acute Myelogenous Leukemia (AML)
• Intervention / Treatment: Drug: N-803

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
      • Masonic Cancer Center at University of Minnesota

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Diagnosis of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for whom an allogeneic hematopoietic stem cell transplant using a reduced intensity conditioning is planned or has been performed and patient is prior to day 60 post-transplant.

2. Able to begin study treatment between day +42 and day +60 after the transplant and meets the following transplant related requirements:

   • Sustained neutrophil (ANC > 1000/mcL) and platelet (> 30,000/mcL) engraftment
   • >50% donor myeloid and lymphoid chimerism blood or bone marrow on most recent bone marrow (BM) evaluation
   • No evidence of recurrent disease on most recent bone marrow evaluation (day 21 or 28 post-transplant is acceptable)
   • No morphologic evidence of relapse (< 5% bone marrow blasts) on most recent BM evaluation (Day 21 or 28 post-transplant is acceptable)
   • Being followed in the outpatient setting (not an inpatient)
   • No plan of giving other anti-cancer treatment directed at diseases under study (i.e. maintenance therapy [e.g. sorafenib for FLT3m+ AML or hypomethylating therapy], additional therapy for MRD)
3. If acute GVHD is present it must be clinically improving on topical steroids and/or on low dose systemic steroids (≤ 0.3 mg/kg/day prednisone) and with clinical stability for at least 1 week prior to determination of eligibility. GVHD prophylaxis will be continued per individual institutional standard practice

4. One of the following donor graft sources used for the transplant:

   • Group 1: sibling donor
   • Group 2: haploidentical donor [with post-transplant cyclophosphamide]
   • Group 3: unrelated donor
   • Group 4: unrelated umbilical cord blood
5. Karnofsky performance status ≥ 70%

6. Adequate organ function within 14 days of study enrollment defined as:

   • Renal: serum creatinine: ≤ 2.0 mg/dL
   • Hepatic: SGOT ≤ 3 x upper limit of institutional normal (ULN)
7. Sexually active females of child-bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy and for 4 months after completion of therapy.
8. Voluntary written consent prior to the performance of any research related procedures

Exclusion Criteria:

1. Prior N-803 (previously known as ALT-803)
2. Pregnant or breastfeeding - N-803 is an investigational agent. Women of child bearing potential must have a negative pregnancy test at screening.
3. Class II or greater New York Heart Association Functional Classification criteria or serious cardiac arrhythmias likely to increase the risk of cardiac complications of cytokine therapy (e.g. ventricular tachycardia, frequent ventricular ectopy, or supraventricular tachyarrhythmia requiring chronic therapy)
4. Marked baseline prolongation of QT/QTc interval (e.g. demonstration of a QTc interval > 500 milliseconds)
5. Active uncontrolled bacterial, fungal, or viral infections - all prior infections must have resolved following optimal therapy and must be afebrile for at least 24 hours at time of enrollment.
6. Active autoimmune disease requiring immunosuppressive therapy (GVHD prophylaxis is permitted per institutional practice)
7. History of severe asthma and currently on chronic medications (mild asthma requiring inhaled steroids only is eligible)
8. Received any investigational agent within the 14 days before the start of study treatment (1st dose of N-803)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: N-803	Drug: N-803; N-803 at 6 mcg/kg SQ Day 1 of a 4 week (28 day) cycle with ± 1 week window Continue N-803 every 4 weeks for 10 doses or until relapse, unacceptable toxicity, or patient refusal, whichever comes earlier.; Other Names: Nant-803

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Relapse	Efficacy of N-803 as measured by the cumulative incidence of relapse between the 1st dose of N-803 and 2 years after a reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplant (alloHCT)	24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Chronic GVHD	Incidence of acute graft-versus-host disease	1 year
Overall Survival	Incidence of overall survival at one year	1 year post transplant
Relapse	Incidence of relapse at 2 years after alloHCT stratified by number of doses of N-803 (1-3 or 4-10)	2 Years
Incidence of Adverse Events	Frequency of all adverse	12 months
Incidence of Acute Graft-versus-host Disease	Incidence of grade 2-4 and grade 3-4 acute graft-versus-host-disease (GVHD)	Day 100
Incidence of Acute Graft-versus-host Disease	Incidence of grade 2-4 and grade 3-4 acute graft-versus-host-disease (GVHD)	Day 180
Minimal Residual Disease (MRD)	Incidence of minimal residual disease (MRD) post-transplant	1 year
Non-Relapse Mortality	Incidence of non-relapse mortality	1 year

Collaborators and Investigators

• Sponsor: Masonic Cancer Center, University of Minnesota
• Investigators: Principal Investigator: Claudio Brunstein, MD, PhD, University of Minnesota

Study record dates

Study Major Dates

• Study Start (Actual): April 12, 2017
• Primary Completion (Actual): March 19, 2022
• Study Completion (Actual): August 31, 2022

Study Registration Dates

• First Submitted: November 2, 2016
• First Submitted That Met QC Criteria: December 7, 2016
• First Posted (Estimated): December 12, 2016

Study Record Updates

• Last Update Posted (Actual): November 3, 2023
• Last Update Submitted That Met QC Criteria: October 10, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Bone Marrow Diseases; Hematologic Diseases; Precancerous Conditions; Myelodysplastic Syndromes; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Preleukemia
• Other Study ID Numbers: 2016LS058; MT2016-07 (Other Identifier: University of Minnesota Masonic Cancer Center)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No